Article
Biotechnology & Applied Microbiology
Alexander Payne, Nadine Holmes, Thomas Clarke, Rory Munro, Bisrat J. Debebe, Matthew Loose
Summary: Nanopore sequencers selectively sequence DNA molecules by reversing voltage, overcome computational limitations with GPU base-calling, enrich specific chromosomes and genes, and enable efficient screening of target gene panels without specialized sample preparation.
NATURE BIOTECHNOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Guilherme Marcelino Viana de Siqueira, Felipe Marcelo Pereira-dos-Santos, Rafael Silva-Rocha, Maria-Eugenia Guazzaroni
Summary: Nanopore sequencing shows potential for community profiling in healthcare settings, although lower throughput may be a limitation. The use of single-use Flongle flowcells in nanopore sequencing runs can provide valuable insights into community composition.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Oncology
Adam Szpechcinski, Malgorzata Szolkowska, Sebastian Winiarski, Urszula Lechowicz, Piotr Wisniewski, Magdalena Knetki-Wroblewska
Summary: The molecular dysregulation of thymic epithelial tumors, including thymomas and thymic carcinomas, is poorly understood. Through next-generation sequencing, this study identified more single nucleotide variants (SNVs) in thymic carcinomas compared to thymomas. Somatic pathogenic gene variants in TP53, ERBB2, KIT, or KRAS were found in a subset of thymic carcinomas, while uncertain clinical significance variants in KIT, ERBB2, and FOXL2 were exclusively found in thymomas. The presence of somatic pathogenic variants was associated with shorter disease-free survival in thymic carcinoma patients. This study expands our understanding of the genetic alterations in these tumors and highlights potential therapeutic targets.
Article
Oncology
Laura Morsberger, Aparna Pallavajjala, Patty Long, Melanie Hardy, Rebecca Park, Rebecca Parish, Azin Nozari, Ying S. Zou
Summary: This study reviewed the results of HER2 IHC and FISH testing in 4884 cases of HER2-positive breast carcinomas and found a small percentage of patients with discordant results. Additionally, determining HER2 amplification status using NGS can provide a more comprehensive genetic analysis for breast carcinomas. This is particularly important for HER2-positive breast carcinomas with negative HER2 IHC results.
CANCER CELL INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Linwei Guo, Yunjin Wang, Wenxiao Yang, Chenchen Wang, Tian'an Guo, Jingcheng Yang, Zhiming Shao, Guoxiang Cai, Sanjun Cai, Liying Zhang, Xin Hu, Ye Xu
Summary: This study conducted tumor genetic testing and analysis on 869 Chinese patients with colorectal cancer (CRC). The results showed that single-gene somatic mutations in BRAF or RBM10 were associated with shorter progression-free survival in patients with metastatic CRC. Co-mutations of KRAS/AMER1 or KRAS/APC were found in the metastatic cohort, leading to poor response to bevacizumab. Moreover, pathogenic germline alterations in the DNA damage repair pathway were identified in a small percentage of patients, with secondary-hit events observed in a significant proportion of these tumors.
Article
Biochemistry & Molecular Biology
Aleksander Salomon-Perzynski, Joanna Barankiewicz, Marcin Machnicki, Irena Misiewicz-Krzeminska, Michal Pawlak, Sylwia Radomska, Agnieszka Krzywdzinska, Aleksandra Bluszcz, Piotr Stawinski, Malgorzata Rydzanicz, Natalia Jakacka, Iwona Solarska, Katarzyna Borg, Zofia Spyra-Gorny, Tomasz Szpila, Bartosz Pula, Sebastian Grosicki, Tomasz Stoklosa, Rafal Ploski, Ewa Lech-Maranda, Jana Jakubikova, Krzysztof Jamroziak
Summary: Tracking genetic changes during multiple myeloma progression reveals different patterns of mutation evolution, with mutation loss pathway associated with better treatment response. Many druggable genes are mutated, even in heavily pre-treated patients. Redefining R-ISS at relapse is clinically valuable.
Article
Oncology
Qi-Wen Wang, Xin-Yuan Wang, Qing-Wei Zhang, Jin-Nan Chen, Yu-Jie Zhou, Zhao-Rong Tang, Rui-Lan Wang, Haoyan Chen, Huimin Chen, Xiao-Bo Li
Summary: This study revealed that individuals with ERBB2 mutations in serrated polyps have a higher risk of colorectal neoplasm recurrence. ERBB2 mutations could serve as predictive markers for high-risk serrated polyps and potentially play a role in the development of colorectal carcinoma through the serrated pathway.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biology
Maria Guarnaccia, Laura Guarnaccia, Valentina La Cognata, Stefania Elena Navone, Rolando Campanella, Antonella Ampollini, Marco Locatelli, Monica Miozzo, Giovanni Marfia, Sebastiano Cavallaro
Summary: The study developed a targeted next-generation sequencing approach for analyzing genetic variations and chromosomal aberrations in gliomas, which can provide accurate and specific assessment of tumor pathogenesis, prognosis, and treatment response. This has important implications for the diagnosis and treatment of gliomas.
Article
Oncology
Kohei Nakamura, Eriko Aimono, Junna Oba, Hideyuki Hayashi, Shigeki Tanishima, Tetsu Hayashida, Tatsuyuki Chiyoda, Takeo Kosaka, Tomoyuki Hishida, Hirohumi Kawakubo, Minoru Kitago, Koji Okabayashi, Takeru Funakoshi, Hajime Okita, Sadakatsu Ikeda, Hiromasa Takaishi, Hiroshi Nishihara
Summary: Assessing the ERBB2 amplification status is vital for determining the best therapeutic strategy in breast and gastric cancer. Results show that NGS-estimated ERBB2 CN can be considered as a diagnostic test for anti-HER2 therapy after adequate clinical trials.
Article
Multidisciplinary Sciences
Charles R. Heller, Stephen David
Summary: The development of large scale neural recordings technology enables researchers to measure the activity of hundreds to thousands of neurons at single cell resolution. Neural decoding analysis is a widely used tool to investigate the information represented in complex neural population activity. However, due to practical constraints, new analytical tools are required to account for limited experimental trial numbers.
Article
Medical Laboratory Technology
Bennett Oh Vic Shum, Carel Jacobus Pretorius, Letitia Min Fen Sng, Ilya Henner, Paulette Barahona, Emre Basar, Jim McGill, Urs Wilgen, Anna Zournazi, Lilian Downie, Natalie Taylor, Liam Cheney, Sylvania Wu, Natalie Angela Twine, Denis Carolin Bauer, Gerald Francis Watts, Akash Navilebasappa, Kishore Rajagopal Kumar, Jacobus Petrus Johannes Ungerer, Glenn Bennett
Summary: The study found that newborn screening can be expanded using targeted gene sequencing (TGS), which is a feasible and cost-effective method. The TGS assay had a high sensitivity (>99%) and specificity (100%) with a turnaround time of 7 to 10 days and a maximum batch size of 1536 samples. This approach can increase the number of conditions screened and improve the effectiveness of newborn screening programs.
CLINICAL CHEMISTRY
(2023)
Article
Immunology
Mengfan Jiao, Xiaoxu Ma, Yaoguang Li, Huifen Wang, Ying Liu, Wenhu Guo, Jun Lv
Summary: mNGS can accurately and rapidly detect Nocardia infection, especially in the diagnosis of mixed infections. The number of infectious species is an independent risk factor for the prognosis of nocardiosis patients.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Medicine, General & Internal
Hassan Thriq, Asma Gul, Muhammad Zubair, Syed Raza Jaffer, Nadeem Zafar, Ghazala Sadaf
Summary: This study tested germline oncogenic mutations in BRCA1 and BRCA2 genes in TNBC patients, detecting two pathogenic variants and three variants of uncertain significance. Patients with pathogenic variants had early onset breast cancer with age less than 35, highlighting the importance of early genetic screening in young patients with positive family history of breast carcinoma.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Article
Oncology
Yanjie Han, Yuanyuan Xiong, Tao Lu, Rongrong Chen, Yuan Liu, Hui Tang, Ruixuan Geng, Yingyi Wang
Summary: HER2-mutant and HER2-amplified NSCLC have different molecular characteristics, and the genomic profile of HER2 NSCLC is dependent on tumor stage. Pyrotinib shows better therapeutic effects than afatinib in HER2 NSCLC patients. Resistance mechanisms to afatinib and pyrotinib, both HER2-dependent and -independent, have been identified.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Ravina Kullar, Emanuele Chisari, James Snyder, Christopher Cooper, Javad Parvizi, Jason Sniffen
Summary: This article discusses the gaps in traditional culture and introduces the utility of next-generation sequencing (NGS) in diagnosing and treating peri-prosthetic joint infections. It highlights the clinical benefits of using NGS compared to culture alone and emphasizes the potential of NGS in improving the yield of identifying infective organisms in challenging cases.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Oncology
Ashley Weir, Eun-Young Kang, Nicola S. Meagher, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S. Anglesio, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H. Brand, James D. Brenton, Angela Brooks-Wilson, Michael E. Carney, Julie M. Cunningham, Kara L. Cushing-Haugen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Sian Fereday, Anna Fischer, Luis Paz-Ares, Javier Gayarre, Blake C. Gilks, Marcel Grube, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Sabine Heublein, Yajue Huang, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Felix K. F. Kommoss, Jennifer M. Koziak, Bernhard Kraemer, Nhu D. Le, Jaime Lesnock, Jenny Lester, Jan Lubinski, Janusz Menkiszak, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Robles-Diaz, Matthias Ruebner, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Helen Steed, Aline Talhouk, Sarah E. Taylor, Nadia Traficante, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Javier Benitez, Andrew Berchuck, David D. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Anna DeFazio, Jennifer A. Doherty, Peter A. Fasching, Maria J. Garcia, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Stefan Kommoss, Francesmary Modugno, Joellen M. Schildkraut, Hans-Peter Sinn, Annette Staebler, Linda E. Kelemen, Caroline E. Ford, Usha Menon, Paul D. P. Pharoah, Martin Koebel, Susan J. Ramus, D. Bowtell, A. DeFazio, N. Traficante, S. Fereday, A. Brand, P. Harnett, R. Sharma
Summary: Recently, a study found a positive correlation between protein expression of FOXJ1 and the 5-year survival rate of patients with tubo-ovarian high-grade serous carcinoma (HGSC). However, protein expression of GMNN was not significantly associated with patient survival. This study provides preliminary evidence for the prognostic value of FOXJ1 in HGSC and validates the prior mRNA-based prognostic association through immunohistochemistry.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel
Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.
Article
Oncology
Benedikt Schafgen, Annabelle Haller, Hans-Peter Sinn, Manuel Feisst, Christina Gomez, Anne Stieber, Juliane Nees, Riku Togawa, Andre Pfob, Andre Hennigs, Johanna Hederer, Fabian Riedel, Sarah Fastner, Joerg Heil, Michael Golatta
Summary: This study aimed to evaluate the accuracy of intraoperative specimen radiography (CSR) in diagnosing breast cancer and reducing second surgeries. The results showed that CSR had low effectiveness in patients treated with neoadjuvant chemotherapy, questioning its routine use and suggesting the need for alternative intraoperative margin assessment tools.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Marc Thill, Cornelia Kolberg-Liedtke, Ute-Susann Albert, Maggie Banys-Paluchowski, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Joerg Heil, Jens Huober, Christian Jackisch, Hans-Heinrich Kreipe, David Krug, Thorsten Kuehn, Sherko Kuemmel, Sibylle Loibl, Diana Lueftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schuetz, Hans Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, Achim Woeckel, Volkmar Mueller, Rachel Wuerstlein, Wolfgang Janni, Tjoung-Won Park-Simon
Summary: The Breast Committee of the German Gynecological Oncology Group (AGO) has released the 2023 update on evidence-based recommendations for diagnosing and treating patients with locally advanced and metastatic breast cancer (mBC).
Article
Oncology
Tjoung-Won Park-Simon, Volkmar Mueller, Christian Jackisch, Ute-Susann Albert, Maggie Banys-Paluchowski, Ingo Bauerfeind, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas D. Hartkopf, Joerg Heil, Jens Huober, Cornelia Kolberg-Liedtke, Hans H. Kreipe, David Krug, Thorsten Kuehn, Sherko Kuemmel, Sibylle Loibl, Diana Lueftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schuetz, Hans Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, Achim Woeckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill
Summary: The updated evidence-based treatment recommendations for early and metastatic breast cancer were released in March 2023 by the German Gynecological Oncology Group. This paper provides a concise summary of the updated recommendations for early breast cancer chapter by chapter.
Article
Oncology
Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmoller, Volkmar Mueller, Frederik Marme, Patrick Soon-Shiong, Valentina Nekljudova, Michae Untch, Sibylle Loibl
Summary: This study aims to explore the role of immune-cell activity in breast cancer tumors in predicting response to neoadjuvant paclitaxel-based therapy and prognosis. The study found that tumors with high immune-cell activity (hot cluster tumors) and relatively higher tumor-infiltrating lymphocytes (TILs) levels were associated with higher rates of pathologic complete response (pCR) and improved survival. It also observed longer disease-free survival and overall survival in patients with hot or warm cluster tumors, particularly in HR-negative tumors, even with lower TIL levels.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Petros Christopoulos, Richard Schlenk, Daniel Kazdal, Miriam Blasi, Jochen Lennerz, Rajiv Shah, Jan Budczies, Nisar Malek, Stefan Froehling, Richard Rosenquist, Peter Schirmacher, Farastuk Bozorgmehr, Jonas Kuon, Martin Reck, Michael Thomas, Albrecht Stenzinger
Summary: Using real-world data (RWD) for drug access is necessary in precision oncology to tackle low-prevalence oncogenic mutations across cancers. However, the implementation varies, and there is a need for transparency, guidance, and a harmonized framework for health technology assessment across the European Union (EU). Infrastructural changes in registries, guidelines, and the health data space are also required.
GENES CHROMOSOMES & CANCER
(2023)
Article
Oncology
Hannah Goldschmid, Klaus Kluck, Markus Ball, Martina Kirchner, Michael Allgaeuer, Hauke Winter, Felix Herth, Claus-Peter Heussel, Soni Savai Pullamsetti, Rajkumar Savai, Timothy Tay Kwang Yong, Peter Schirmacher, Solange Peters, Michael Thomas, Petros Christopoulos, Jan Budczies, Albrecht Stenzinger, Daniel Kazdal
Summary: Intratumoral heterogeneity is a significant factor in resistance to lung cancer therapies, and spatial heterogeneity of the tumor microenvironment is associated with genetic properties of the tumor, which is particularly important in therapy-naive patients.
Letter
Biochemistry & Molecular Biology
A. L. Illert, A. Stenzinger, M. Bitzer, P. Horak, V. I. Gaidzik, Y. Moeller, J. Beha, Oe Oener, F. Schmitt, S. Lassmann, S. Ossowski, C. P. Schaaf, M. Hallek, T. H. Bruemmendorf, P. Albers, T. Fehm, P. Brossart, H. Glimm, D. Schadendorf, A. Bleckmann, C. H. Brandts, I Esposito, E. Mack, C. Peters, C. Bokemeyer, S. Froehling, T. Kindler, H. Alguel, V Heinemann, H. Doehner, R. Bargou, V. Ellenrieder, P. Hillemanns, F. Lordick, A. Hochhaus, M. W. Beckmann, T. Pukrop, M. Trepel, L. Sundmacher, S. Wesselmann, G. Nettekoven, F. Kohlhuber, O. Heinze, J. Budczies, M. Werner, K. Nikolaou, A. J. Beer, G. Tabatabai, W. Weichert, U. Keilholz, M. Boerries, O. Kohlbacher, J. Duyster, R. Thimme, T. Seufferlein, P. Schirmacher, N. P. Malek
Article
Endocrinology & Metabolism
A. Marshall, K. F. Kommoss, H. Ortmann, M. Kirchner, J. Jauckus, P. Sinn, T. Strowitzki, A. Germeyer
Summary: This study molecularly characterized the gene expression signatures of adenomyosis uteri (FA) and deep infiltrating endometriosis (DIE). The results showed significant differences in RNA expression levels between the two diseases. Genes belonging to the PI3K pathway were highly expressed in DIE, while genes belonging to the RAS pathway were highly expressed in FA.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2023)
Article
Cell Biology
Eva Romanovsky, Klaus Kluck, Iordanis Ourailidis, Michael Menzel, Susanne Beck, Markus Ball, Daniel Kazdal, Petros Christopoulos, Peter Schirmacher, Thorsten Stiewe, Albrecht Stenzinger, Jan Budczies
Summary: TP53 is the most frequently mutated gene in human cancer. mRNA expression analysis in 24 cancer types revealed consistent expression patterns, differential gene expression associated with different TP53 mutation types, and cancer type-specific gene expression and immune infiltration patterns. These findings support the evaluation of TP53 mutations as predictive markers for immunotherapy and targeted therapies.
CELL DEATH DISCOVERY
(2023)
Article
Pathology
Zsuzsanna Varga, Peter Sinn, Annette Lebeau
Summary: B3 lesions of the breast are a diverse group of lesions with uncertain malignant potential that present histologically distinct alterations. They are typically detected through mammographic calcifications or mass lesions and can include atypical ductal hyperplasia, classic lobular neoplasia, flat epithelial atypia, papillomas, fibroepithelial tumors, and other rare lesions. Immunohistochemical staining is useful in differentiating these lesions and guiding proper classification. The radiological-pathological correlation is crucial for the clinical management of B3 lesions.
Article
Pathology
Christina C. Westhoff, Annette Ramaswamy, Matthias Kalder, Annette Lebeau, Peter Sinn, Carsten Denkert
Summary: Immunohistological examinations are useful for diagnosing breast carcinoma in various clinical situations. This review article summarizes different immunohistological options, including diagnostic, prognostic, and predictive markers. A quantitative, quality-controlled, and validated diagnostic approach is essential, especially when therapeutic decisions are based on immunohistological expression patterns. This article provides a practical summary of important immunohistochemical markers for routine breast cancer diagnosis and differentiation between malignant and benign lesions.
Article
Pathology
Hans-Peter Sinn, Zsuzsanna Varga
Summary: Triple-negative breast cancer (TNBC), accounting for about 10% of breast cancer cases, lacks expression of estrogen and progesterone receptors and overexpression or amplification of HER2. TNBC differs by younger age, association with BRCA1 mutation, and low differentiation from hormone receptor-positive breast cancer. It exhibits considerable heterogeneity both morphologically and molecularly, including different subtypes with variable gene expression patterns. Therefore, it is recommended to critically use the term TNBC considering histopathological tumor differentiation.